A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT03743064 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 318
Last updated 2024-06-26
Summary
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia (cancer-related weight loss). The main question it aimed to answer was as follows: Do patients who receive anamorelin HCl gain more body weight and show more improvement in anorexia symptoms than those who receive placebo.
Approximately 316 patients were to be enrolled in the study. Of these patients, an equal number were to be assigned to each treatment group (anamorelin HCl or placebo). Participants were to take their assigned study drug by mouth once daily for a total of 24 weeks. During this treatment period, the patients were to visit the clinical study site every 3 weeks for health and other study-related assessments. Two weeks after the last treatment, patients were to receive a follow-up phone call.
Conditions
- Cachexia; Cancer
- Non Small Cell Lung Cancer
Interventions
- DRUG
-
anamorelin HCl
100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
- DRUG
-
Placebo Oral Tablet
Placebo (administered as matching placebo tablets in the fasted condition)
Sponsors & Collaborators
-
Helsinn Healthcare SA
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-06
- Primary Completion
- 2022-12-27
- Completion
- 2022-12-27
- FDA Drug
- Yes
Countries
- United States
- Australia
- Belgium
- Croatia
- Poland
- Romania
- Russia
- Ukraine
Study Locations
More Related Trials
-
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
NCT00040885 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT01355484 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT00033553 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
NCT01788566 ·Status: COMPLETED ·Phase: PHASE2
-
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
NCT03732846 ·Status: UNKNOWN ·Phase: PHASE2
-
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
NCT06909383 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00391274 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
NCT03781869 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC
NCT00001450 ·Status: COMPLETED ·Phase: PHASE2
-
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT04475939 ·Status: COMPLETED ·Phase: PHASE3
-
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
NCT04254471 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
NCT03780283 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
NCT06247605 ·Status: RECRUITING ·Phase: PHASE3
-
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
NCT00976677 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT00126581 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)
NCT06772454 ·Status: RECRUITING
-
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Single Arm on the Tolerability of Weekly Nab-paclitaxel
NCT01702844 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
NCT00866970 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
NCT01355497 ·Status: COMPLETED ·Phase: PHASE3
-
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00005646 ·Status: COMPLETED ·Phase: PHASE2
-
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
NCT00174356 ·Status: COMPLETED ·Phase: PHASE1
-
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06931145 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
NCT02579564 ·Status: UNKNOWN ·Phase: PHASE3